Our results demonstrate that sEVs are crucial to cancer progression by driving the hyperactivation of the TGF-β signaling in breast cancer cells, which helps to explain the failure of TGF-β signaling inhibitors in cancer clinical trials. This evidence concerns the gene TGFB1 and cancer.